Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 4/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | BCL9 | O00512 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1935058 | 1.00 | MAPT (0.66) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1935059 | 1.00 | MAPT (0.66) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL6624647 | 0.91 | MAPT (0.59) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20631080 | 0.91 | MAPT (0.59) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL13495646 | 0.89 | ALDH1A1 (0.57) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8171177 | 0.88 | ALDH1A1 (0.54) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL31591663 | 0.88 | ALDH1A1 (0.55) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL12396358 | 0.87 | MAPT (0.53) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2158928 | 0.87 | MAPT (0.53) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29401562 | 0.86 | MAPT (0.52) | MAPTALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0189803-B1 | INDOL-3-YL-QUINAZOLINO-1,4-BENZODIAZEPIN-5,13-DIONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1990-04-25 | — | — | EP | claimed |
| EP-0189803-A1 | Indol-3-yl-quinazolino-1,4-benzodiazepin-5,13-diones, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-08-06 | — | — | EP | claimed |
| US-4559339-A | CENTRAL NERVOUS SYSTEM, GASTROINTESTINAL DISORDERS | MERCK & CO., INC. (US) | 1985-12-17 | — | — | US | claimed |
| CN-113195641-B | Sulfoxonium ylide derivatives as probes for cysteine proteases | 武田药品工业株式会社 | 2024-09-03 | — | — | CN | disclosed |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-14 | — | — | US | disclosed |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-14 | — | — | US | disclosed |
| EP-3118211-B1 | AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA-AND/OR DNA-CONTAINING VIRUSES AND CONCOMITANT DISEASES | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU PHARMENTERPRISES (RU) | 2022-10-12 | — | — | EP | disclosed |
| WO-2022041126-A1 | GLYCYRRHIZIC ACID DERIVATIVE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 林振文 | 2022-03-03 | — | — | WO | disclosed |
| CN-113195641-A | Sulfoxonium ylide derivatives as probes for cysteine proteases | 武田药品工业株式会社 | 2021-07-30 | — | — | CN | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
| EP-0198192-A1 | 7-Amino-1-(subst.cyclopropyl)-1,4 -dihydro-4-oxo-quinoline carboxylic acids, method for their preparation, and antibacterial agents containing them | BAYER AG (DE) | 1986-10-22 | — | — | EP | disclosed |
| EP-0189803-A1 | Indol-3-yl-quinazolino-1,4-benzodiazepin-5,13-diones, process for their preparation and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1986-08-06 | — | — | EP | disclosed |
| EP-0167763-A1 | 7-Amino-1-cyclopropyl-6,8-dihalo-1,4-dihydro-4-oxo-3-quinoline-carboxylic acids, process for their preparation and bactericidal agents containing them | BAYER AG (DE) | 1986-01-15 | — | — | EP | disclosed |
| EP-0164619-A1 | 2,4,5-Trihalo or 2,3,4,5-tetrahalo benzene derivatives and process for producing them | BAYER AG (DE) | 1985-12-18 | — | — | EP | disclosed |
| US-4559341-A | Quinolonecarboxylic acids and antibacterial agents containing these compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1985-12-17 | — | — | US | disclosed |
| US-4559339-A | CENTRAL NERVOUS SYSTEM, GASTROINTESTINAL DISORDERS | MERCK & CO., INC. (US) | 1985-12-17 | — | — | US | disclosed |
| US-4556658-A | 7-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acids and antibacterial agents containing these compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1985-12-03 | — | — | US | disclosed |
| EP-0126355-A1 | 7-Amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinoline-carboxylic acid, processes for their preparation and antibacterial agents containing them | BAYER AG (DE) | 1984-11-28 | — | — | EP | disclosed |
| EP-0117473-A1 | Quinolone carboxylic acids, process for their preparation and antibacterial compositions containing them | BAYER AG (DE) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | MAPT 4350/4885ALDH1A1 949/4885SMN1; SMN2 4069/4885 |
| US-20230285598-A1 | SULFOXONIUM YLIDE DERIVATIVES AS PROBES FOR CYSTEINE PROTEASE | CTSZ, CTSF, CTSL | MAPT 4365/4885ALDH1A1 1150/4885SMN1; SMN2 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.